No Data
No Data
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the
Jefferies Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
Jefferies analyst Kelly Shi maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $94.According to TipRanks data, the analyst has a success rate of 30.4% and a total
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $60 to $94
On May 24, major Wall Street analysts update their ratings for $Legend Biotech(LEGN.US)$, with price targets ranging from $60 to $94.Jefferies analyst Kelly Shi maintains with a buy rating, and mainta
Jefferies Issues a Buy Rating on Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Merus (MRUS) and Agilon Health (AGL)
Deutsche Bank Starts Legend Biotech With Buy Rating
Legend Biotech (LEGN) has an average rating of outperform and price targets ranging from $60 to $95, according to analysts polled by Capital IQ.